Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07160244

PHASE3

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

Sponsor: Pfizer

View on ClinicalTrials.gov

Summary

BEATRIX (group B strEptococcus mATeRnal and Infant VaX study) The purpose of this study is to learn about the safety and how the group B streptococcus (GBS) vaccine works in pregnant women and their babies. This study is seeking healthy pregnant participants: * aged 49 or younger who can join. * between 24 and 36 weeks of gestation ("Gestational age" is a medical term used to describe how far along your pregnancy is) * had a fetal ultrasound examination performed with no major fetal abnormalities observed * documented negative for HIV, syphilis and Hepatitis B All participants in this study will receive only 1 shot in an arm. This could either be a group B streptococcus 6-valent polysaccharide conjugate vaccine (GBS6) or placebo. Placebo is an inactive substance used in the study for comparison purposes; in this study, the placebo injection will be saline (saltwater). The pregnant participants may take part in this study for a maximum of 14 months (6 months after delivery) , and their babies for about 12 months after they are born. The pregnant participants will need to visit the research site at least 3 to 4 times with some visits permitted to occur over the telephone. A subset of infants will be asked to take part in the study for up to 19 months. The subset will receive diphtheria toxoid-containing vaccine and/or pneumococcal vaccine following each country's standard immunization plan and have blood drawn 1 month after completion of the primary and/or toddler (booster) doses.

Official title: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants

Key Details

Gender

All

Age Range

1 Day - 49 Years

Study Type

INTERVENTIONAL

Enrollment

6000

Start Date

2025-08-25

Completion Date

2029-03-02

Last Updated

2026-02-04

Healthy Volunteers

Yes

Conditions

Healthy

Interventions

BIOLOGICAL

Multivalent Group B streptococcus vaccine

BIOLOGICAL

Placebo

Saline Control

BIOLOGICAL

Infanrix hexa

Vaccine administered in a subset of infant participants as per the national immunization schedule

BIOLOGICAL

Prevenar 20

Vaccine administered in a subset of infant participants as per the national immunization schedule

BIOLOGICAL

Pediarix

Vaccine administered in a subset of infant participants as per the national immunization schedule

BIOLOGICAL

Prevnar 20

Vaccine administered in a subset of infant participants as per the national immunization schedule

BIOLOGICAL

Infanrix

Vaccine administered in a subset of infant participants as per the national immunization schedule

Key Inclusion criteria- Maternal: * Healthy pregnant women ≤49 years of age who are between 24 0/7 and 36 0/7 weeks of gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, and who have no known increased risk of complications. * Had a fetal anomaly ultrasound examination with no significant fetal abnormalities observed. * Documented negative human immunodeficiency virus (HIV) antibody test, syphilis test, and hepatitis B virus (HBV) surface antigen test during this pregnancy and prior to randomization. * Capable of giving personal signed informed consent. * Willing to give informed consent for her infant to participate in the study. Key Exclusion criteria- Maternal: * Prepregnancy body mass index (BMI) of \>40 kg/m2. * Current pregnancy complications or abnormalities that may increase the risk associated with the participation in and completion of the study. * Prior pregnancy complications or abnormalities that, based on the investigator's judgment, may increase the risk associated with the participation in and completion of the study. * History of microbiologically proven invasive disease caused by GBS in the current pregnancy. * A known or suspected infection during the current pregnancy that may increase the risk of complications in pregnancy (eg, active tuberculosis, syphilis, primary genital herpes simplex, malaria). Key Inclusion criteria- Infant Participants \- Evidence of a signed and dated ICD signed by the parent(s)/legally authorized representative or legal guardian Key Exclusion Criteria - Infant Participants: \- Children or grandchildren who are direct descendants of investigator site staff or sponsor and sponsor delegate employees directly involved in the conduct of the study. Key Exclusion Criteria - Infant immunogenicity subset Participants: \- Children with a known or suspected contraindication to any vaccine administered in the infant vaccine immunogenicity subset. Refer to the study contact for further eligibility details

Locations (105)

SEC Clinical Research

Dothan, Alabama, United States

ClinMed

Phoenix, Arizona, United States

Genesis OB/GYN

Tucson, Arizona, United States

Eclipse Clinical Research

Tucson, Arizona, United States

Antelope Valley Medical Center

Lancaster, California, United States

Chemidox Clinical Trials

Lancaster, California, United States

South Florida Clinical Research Institute - Margate

Margate, Florida, United States

Citadelle Clinical Research

North Miami Beach, Florida, United States

Emerald Coast OBGYN Clinical Research

Panama City, Florida, United States

HCA Florida Gulf Coast Hospital

Panama City, Florida, United States

Advanced Specialty Research

Boise, Idaho, United States

Express Lab

Garden City, Idaho, United States

Clinical Research Prime

Idaho Falls, Idaho, United States

Eastern Idaho Regional Medical Center

Idaho Falls, Idaho, United States

Mountain View Hospital

Idaho Falls, Idaho, United States

Madison Memorial Hospital

Rexburg, Idaho, United States

Accellacare - McFarland

Ames, Iowa, United States

Mary Greeley Medical Center

Ames, Iowa, United States

McFarland Clinic, PC

Ames, Iowa, United States

Velocity Clinical Research, Covington

Covington, Louisiana, United States

Boston Medical Center

Boston, Massachusetts, United States

Washington University School of Medicine

St Louis, Missouri, United States

Boeson Research GTF

Great Falls, Montana, United States

Origin Health GTF

Great Falls, Montana, United States

Boeson Research MSO

Missoula, Montana, United States

Origin Health

Missoula, Montana, United States

Velocity Clinical Research, Grand Island

Grand Island, Nebraska, United States

Midwest Children's Health Research Center